Pierre A. MORGON is CEO of MRGN Advisors, Co-Founder and CEO at Ibex Therapeutics, Co-Founder and Director at Anemos Therapeutics.
He is Chairman of the Boards of Limula and Baar Therapeutics, as well as Non-Executive Director to the Boards of Barinthus Bio, Univercells, CanSino Biologics Switzerland, IABS (International Alliance for Biological Standardization) and GCRI (The Global Centre for Risk and Innovation).
He supports private equity and venture capital entities as an advisor/venture partner, including LifeScienceX, Merieux Equity Partners, RocketBio Capital, AVM Management and Osinvest International.
Pierre has over 35 years of experience in the global pharmaceutical and biological industry, both at the helm of operations (from business unit head to general manager and CEO) and in marketing and commercial positions (from product marketing at country level to global marketing strategy). Through these local and global positions, he has acquired direct experience with blockbuster products in diverse markets (primary care, specialty care, hospital, vaccines, and biotechnology), geographies (US, Europe, Japan, China, India, Emerging Markets) and organizations.
He spent 2 years at ICI-Pharma, followed by 8 years at Synthelabo, then a division of L’Oreal, followed by 6 years at Aventis Pasteur. Then he had diversified C-level and senior executive management experiences at Yamanouchi Pharma, BMS, Drug Abuse Sciences, Schering-Plough, Bio Alliance Pharma, Sanofi Pasteur, Cegedim and AJ Biologics.
He is a lecturer in several MBA programs and in life science conferences, and at the Mass Challenge incubator in Switzerland where he is also a mentor for start-up life sciences companies.
He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA, and he is an alumnus of INSEAD and IMD.